iShares ESG MSCI USA Min Vol Factor ETF(ESMV.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
iShares ESG MSCI USA Min Vol Factor ETF
ESMV.US
News
View More

IBM Unveils Strategy to Integrate AI Across Business Operations, Prioritizing Innovation and Revenue Growth by 2030

IBM has announced a strategic shift to integrate AI across all business operations by 2030, planning to increase AI investments by 150%. The focus will shift from efficiency to innovation, with 62% of AI spending dedicated to innovation, up from 47%. The strategy includes embedding advanced AI models into products, transforming workforce priorities, and preparing for emerging technologies like quantum computing to drive measurable business outcomes and future growth.

Reuters·
US
IBM
+2.59%
Reuters·
US
IBM
+2.59%

Northrop Grumman Expands Propulsion Innovation with New Maryland Facility

Northrop Grumman Corporation has announced advancements in propulsion technology and space manufacturing at its Maryland sites, including the rapid development of a 21-inch second-stage solid rocket motor for the U.S. Navy. The company is constructing a 57,000-square-foot Propulsion Innovation Center in Elkton to enhance production of hypersonic and solid rocket motor components. These efforts have shown strong alignment between digital modeling and real-world performance, alongside improvements in supply chain resilience.

Reuters·
US
NOC
+1.88%
Reuters·
US
NOC
+1.88%

Key facts: B of A Raises IBM Price Target to $335; UBS Highlights Quantum Tech

B of A Securities has increased its price target for IBM shares from $315.00 to $335.00.1UBS analysts emphasized the potential of quantum computing to transform the industry, specifically mentioning IBM's superconducting and trapped-ion systems as key technologies for future advancements.2

TradingView·
US
IBM
+2.59%
TradingView·
US
IBM
+2.59%

JPM26: Vertex hopes to match cystic fibrosis success in pain and kidney disease

Vertex Pharmaceuticals aims to expand its portfolio beyond cystic fibrosis (CF) with plans for five launches in five disease areas by 2028. CEO Reshma Kewalramani announced at the J.P. Morgan Healthcare conference that the company is focusing on non-opioid pain and renal therapies, including the FDA-approved Jounravx for acute pain. Vertex also has breakthrough designations for renal treatments and plans to file for gene therapy approval for sickle cell disease in children. The goal is to replicate CF success in these new areas.

Pharmaceutical Technology·
US
VRTX
+0.56%
Pharmaceutical Technology·
US
VRTX
+0.56%

Aircraft startup JetZero raises $175 million in Series B funding

JetZero, a California-based startup, has raised $175 million in Series B funding to advance its blended-wing aircraft development aimed at reducing fuel consumption. The funding round was led by B Capital, Northrop Grumman, and venture arms of United Airlines, 3M, and RTX. JetZero plans to use the capital to accelerate its prototype aircraft, expected to achieve 30% better aerodynamics than traditional designs, with its first flight scheduled for 2027. The company has secured over $1 billion in funding and aims for commercial service in the early 2030s.

Reuters·
US
UAL
-2.18%
US
NOC
+1.88%
Reuters·
US
UAL
-2.18%
US
NOC
+1.88%
© 2026 Longbridge｜Disclaimer